Abstract In general, the presence of metabolic syndrome is associated with significant cardiovascular mortality and represents a growing public health concern in the USA. Patients with schizophrenia have a three times greater risk of death than the general population, with cardiovascular disease being the most common cause of this mortality. Use of atypical antipsychotics (AAPs) to treat schizophrenia contributes significantly to this cardiovascular risk. While several different clinical guidelines currently exist to monitor the metabolic consequences of AAP use, implementation is lacking. Because of under-monitoring of side effects and the lack of alternative treatment choices in schizophrenia, research has focused on identification of various biomarkers and pharmacogenomic targets to focus on the patients at greatest risk of metabolic syndrome, thus aiming to increase the efficacy and minimize the side effects of AAPs. This has led to several different lines of research. This review focuses on summarizing the differing metabolic syndrome criteria, monitoring guidelines for use of AAPs, and the role of folic acid as it relates to metabolic syndrome within the schizophrenia population. It concentrates not only on the pharmacogenomics of folic acid metabolism but also on its epigenetic interaction with the environment. From this work, genetic variation within both the methylenetetrahydrofolate reductase (MTHFR) gene and the catechol-O-methyltransferase (COMT) gene has been associated with an increased risk of metabolic syndrome in schizophrenia patients treated with AAPs. Furthermore, work on the combination of folate pharmacogenetics and epigenetics has uncovered relationships between methylation, schizophrenia disease, treatment type, and metabolic syndrome. Despite several areas of biomarker research into schizophrenia-related metabolic syndrome, translation into the clinical setting is still lacking, and further studies are needed to bridge this gap. In the future, folate supplementation may prove to be an easy and effective clinical tool for prevention and/or treatment of metabolic syndrome associated with AAP treatment, but clearly more research needs to be done in this area.
Introduction
In the general population, the presence of metabolic syndrome is associated with significant cardiovascular mortality and represents a growing public health concern in the USA [1, 2] . While the term 'metabolic syndrome' has been coined within the past 20 years (previously called syndrome X), the constellation of symptoms that make up metabolic syndrome (such as central adiposity and elevations in cholesterol levels, blood glucose levels, and blood pressure) have historically been recognized as risk factors for cardiovascular disease [3] [4] [5] . Metabolic syndrome is seen in about 25 % of men and women [6] . For those meeting metabolic syndrome criteria, the populationattributable risk estimates for cardiovascular disease, coronary heart disease, and diabetes mellitus are 34, 29, and 62 %, respectively, for men and 16, 8, and 47 %, respectively, for women [7] . Thus, the presence of metabolic syndrome criteria is associated with an increased risk of significant cardiovascular morbidity and mortality, and has undoubtedly become a national health crisis as the rates of this illness continue to rise. Unfortunately, the risk of metabolic syndrome in patients with a serious mental illness such as schizophrenia or bipolar disorders is more than double that seen in the general population, which has also resulted in a significant proportion of the morbidity and mortality seen within these populations [8] [9] [10] . Although the exact cause of the increased risk of metabolic syndrome in serious mental illness is unknown, the high prevalence of atypical antipsychotic (AAP) use has been suggested as being a major contributor [8, 11] . Much work has been done to examine the pharmacogenomics of AAP metabolic consequences; however, consensus regarding these risks currently does not exist. One promising line of work has focused on folic acid and its pharmacogenetically regulated metabolism through the methylenetetrahydrofolate reductase (MTHFR) enzyme. Thus, the purpose of this review is to focus on the increased risk of metabolic syndrome within the schizophrenia population. It gives a brief background examining the different criteria used for diagnosis of metabolic syndrome, followed by a summary regarding monitoring for metabolic syndrome within the schizophrenia population. Lastly, the role of biomarkers for detection of metabolic syndrome within schizophrenia is touched on, with a summary of the available literature regarding folate pharmacogenomics and epigenomics in antipsychoticassociated metabolic syndrome within this population.
Criteria for Diagnosis of Metabolic Syndrome
Before the increased incidence of metabolic syndrome within the schizophrenia population is discussed, it is necessary to have a thorough understanding of the different criteria that are currently available. Although there is a significant overlap between these differing criteria, there is no one set of criteria that is consistency used by all and, as such, this lack of consistency makes it difficult to compare the rates of metabolic syndrome across populations. Additionally, differing patient populations (i.e. treatmentnaive and non-treatment-naive) are often included when the true incidence of metabolic syndrome due to AAP use is examined. Thus, current estimates range from 13.4 %, as seen within the CAFE (Comparison of Atypicals for First Episode) trial [8] , which included younger drug-naive subjects, to 40-52 %, as reported in the CATIE (Clinical Antipsychotic Trials of Intervention Effectiveness) trial, as well as other recent larger database studies that did not include treatment-naive subjects [9, 11, 12] .
Looking at the different criteria available for the diagnosis of metabolic syndrome, those defined by the National Cholesterol Education Program (NCEP) in 2001 and the International Diabetes Federation (IDF) in 2006 [13, 14] appear to be the most commonly cited and referenced criteria when the overall risk in schizophrenia is examined. In examining the NCEP criteria, it can be seen that a diagnosis of metabolic syndrome can be given when patients meet at least three of the following criteria: abdominal obesity (waist circumference C40 inches in males or C35 inches in females), elevated triglyceride levels (C150 mg/dL, or drug treatment for elevated triglyceride levels), low HDL levels (\40 mg/dL in men or \50 mg/dL in women, or drug treatment for low HDL levels), elevated blood pressure (C130/85 mmHg, or use of antihypertensive medication), or elevated fasting glucose levels (C100 mg/dL, or use of medication for diabetes) [15] . This popular NCEP definition, which was subsequently updated with a lower impaired fasting glucose threshold by the American Heart Association in 2005, was published in the third Adult Treatment Protocol (ATP III-A). Since 2001, various definitions have typically been updates of the original ATP III definition [16] , and so these competing definitions have significant overlap with key components such as glucose dysregulation and central adiposity. It is only the NCEP ATP III-A guidelines that do not require any core elements to be present for a diagnosis of metabolic syndrome. In contrast to this, both the IDF and the European Group for the Study of Insulin Resistance require either a body mass index of [30 kg/m 2 or elevated insulin levels, respectively, as part of their core definitions. Thus, for all of these guidelines, at the heart of each are the same core risk factors; it is just how they are used in defining a diagnosis of metabolic syndrome that potentially allows for some of the variation seen in the incidence of metabolic syndrome within seriously mentally ill populations. To overcome this, some groups have worked together to create a more symbiotic approach to developing metabolic syndrome criteria (with added ethnic and race specificity) such as the consensus definition suggested by Alberti et al. [17] . Thus, while it is easy to understand that the presence of metabolic syndrome confers an increased risk of cardiovascular disease, understanding the specific criteria that need to be met in order to obtain this diagnosis is often not so simple, which may contribute to the confusion often associated with metabolic syndrome and its diagnosis [18] . The anticipated release of the ATP IV guidelines, however, could result in another update of the definition and criteria for metabolic syndrome, and could possibly include ethnic and race specificity, which may further complicate this issue.
Metabolic Syndrome Within Schizophrenia
The presence of a mental illness has long been associated with increased overall mortality [19] [20] [21] . Cardiovascular disease undoubtedly also contributes to excess morbidity and mortality in individuals with a serious mental illness. In patients with schizophrenia, it is estimated that approximately 34 % of deaths among male patients and 31 % of deaths among female patients are attributed to cardiovascular disease, which is surpassed only by suicide as a cause of death [20, 22] . In general, schizophrenia is an often debilitating mental illness, which affects approximately 1 % of the population [23] , usually manifesting not only through positive and negative symptoms, but also as significant cognitive dysfunction [24] . The overall goal of treatment for schizophrenia is remission of symptoms and, for most individuals with schizophrenia, antipsychotic medications play an important role in this process. While our pharmacotherapeutic treatment choices for schizophrenia have expanded over the last few decades, pharmacologically these medications traditionally achieve their effect through blockade of the dopamine 2 receptor [25] . More recently, AAPs (olanzapine, clozapine, risperidone, paliperidone, iloperidone, quetiapine, asenapine, lurasidone, aripirazole, and ziprasidone) have become the firstline treatment for schizophrenia because of their differing serotonin antagonism (primarily at serotonin [5-HT 2A and 5-HT 2C ] receptors), their possible association with negative symptom improvement, and their attenuation of extrapyramidal side effects [26] .
Although AAPs are effective for treatment of schizophrenia, their use has now become commonplace in other mental illnesses and younger age groups as well. Most AAPs carry significant risks such as diabetes, weight gain, and dyslipidemia which, as previously discussed, make up the constellation of cardiovascular risk factors outlined in the metabolic syndrome criteria [27] [28] [29] [30] . Patients taking AAPs frequently manifest early symptoms of metabolic syndrome followed by actual development of more serious cardiac complications. The end result is up to 30 years of life lost [22, 31] for those with schizophrenia. Furthermore, recent studies have suggested that the standardized mortality ratio for cardiac disease may be increasing in schizophrenia patients, relative to the general population, following the introduction of AAPs [32, 33] . These findings are particularly concerning, given the known association between these medications and cardiovascular risk factors, adding biological plausibility to the epidemiological findings. A comparison between the CATIE trial participants with schizophrenia and matched controls from the Third National Health and Nutrition Examination Survey (NHANES III) with regard to the 10-year risk of coronary heart disease, based on the Framingham Heart Study formula, demonstrated an elevation in the risk of coronary heart disease of 34 % in males and 50 % in females with schizophrenia [34] . Similar elevations in cardiac risk in patients with schizophrenia have been demonstrated in other studies [35, 36] and are much higher than the risks reported in the Framingham Heart Study Offspring Study [34] .
Until recently, significant weight gain with AAP use was the primary research focus involving AAP metabolic complications and, in fact, CATIE showed that over 30 % of subjects gained greater than 7 % of their baseline body weight with at least 18 months of AAP treatment [37] . This trial also confirmed that, overall, men and women with schizophrenia were 85 and 137 % more likely to develop metabolic syndrome, respectfully, than NHANES matched controls [9] and that ''[c]linical attention must be given to monitoring for this syndrome and minimizing the risks associated with antipsychotic treatment''. This work has been replicated by other groups, showing that schizophrenia patients treated with AAPs have a 2-to 4-fold greater risk of metabolic syndrome than the general population [38] . The precise explanation for this increased risk linked to AAPs remains unknown; however, the body of literature regarding the risks seen with AAP use has grown substantially throughout the last decade [39] . In addition, recent guidelines based on this work have been developed in an effort to help mitigate the cardiovascular risks seen with AAP use in persons with a serious mental illness.
Monitoring Recommendations for Atypical Antipsychotic Use in Schizophrenia
Although much of this literature attributes the risk of metabolic syndrome in the seriously mentally ill population to AAP use, not all clinicians agree that this is simply a medication-associated side effect. Regardless of the etiology, there is consensus regarding the importance of routine monitoring for metabolic syndrome within the mental health population, and several specific guidelines have been published for patients receiving an AAP. The first of these guidelines was authored in the USA and was published on behalf of the American Diabetes Association (ADA) and the American Psychiatric Association (APA) in 2004 [40] . Key to these guidelines is routine monitoring of the patient's weight, waist circumference, blood pressure, fasting plasma glucose level, and fasting lipid profile. Table 1 is a summary of the APA/ADA monitoring guideline recommendations. In addition to these practice guidelines, several others have been published, such as those supported by the UK's National Institute for Health and Clinical Excellence (NICE) and the Quality and Outcomes Framework (QOF) [41, 42] , as well as publications in the Canadian Journal of Psychiatry [43, 44] . Finally, much work has looked at the quality of proposed guidelines for monitoring metabolic syndrome within schizophrenia, which is beyond the scope of this review; however, several reviews are available [45, 46] . While there might be slight differences in the exact monitoring that these various guidelines recommend; they all highlight the importance of continued monitoring and preventative care for patients with a serious mental illness, especially in those populations receiving AAPs. Unfortunately, the reality is that, despite clear recommendations, these guidelines are not being followed [47] [48] [49] [50] . Adherence to these guidelines has recently become a priority research area for many in an effort to document some of the health disparities related to patients with a serious mental illness. In a recent meta-analysis on this topic, Mitchell et al. found 48 studies on the topic of metabolic monitoring in mental health [46] . As part of their meta-analysis, they found that across these studies, the rate of routine baseline monitoring was very low and only blood pressure and triglyceride monitoring were occurring in more than half of the patients receiving an AAP. More specifically, weight was only monitored in 48 % of patients, followed by glucose levels in 44 %, cholesterol levels in 42 %, and lipid levels and glycosylated hemoglobin levels in fewer than 25 % of patients. Thus, while we have many different monitoring guidelines to choose from, which can be used to guide the treatment of patients with a serious mental illness, these recommendations are not being consistently followed. Additionally, these authors examined the literature regarding monitoring changes that occurred after specific educational interventions were provided for clinicians regarding these guidelines. They found that monitoring of aspects such as blood pressure, weight gain, glucose levels, and lipid levels did increase but that, overall, the rates of monitoring were still low related to glucose levels (56 %) and lipid levels (29 %) [46] . The low usage of these guidelines in clinical practice is of concern and indicates that this patient group does not receive adequate testing or monitoring for metabolic complications. Furthermore, clinicians must use this monitoring to guide treatment of identified metabolic abnormalities with appropriate medications in order to prevent future cardiovascular consequences of metabolic syndrome.
While monitoring for metabolic complications of AAP use continues to be an emphasized issue, the research community has continued to work toward understanding the mechanisms behind these medication side effects, resulting in identification of different biomarkers, which have been proposed for potential use in clinical practice [25, [51] [52] [53] [54] . Potentially, having a biomarker for the metabolic side effects seen with AAP use would be highly desirable, as it would allow the clinician to easily measure a patient's risk of metabolic syndrome before any medication is administered. This would aid in the effort to personalize mental illness pharmacotherapy and optimize treatment. While the research on various biomarkers related to the risk of weight gain and metabolic syndrome seen with AAPs is fairly expansive [54] [55] [56] , no definitive recommendations have yet been translated into clinical practice, and thus work within this area must continue.
Folic Acid Pharmacogenetics and Epigenetics
Our continued understanding of the pharmacogenomics of antipsychotic-associated metabolic syndrome has highlighted the importance of environment and nutrition in the body's ability to regulate the genome [57] though dietary folic acid intake and its pharmacogenetically regulated metabolism. Briefly, folate is a water-soluble B-vitamin involved in synthesis, repair, and methylation of DNA [58] , whose effective utilization is dependent on adequate daily intake as well as genetically altered metabolism [58] . Within the AldoMet cycle, the MTHFR enzyme metabolizes folate to methyltetrahydrofolate (5-methyl THF), which then converts homocysteine into methionine and adenosyl methionine via methionine synthetase (MTR) (Fig. 1) . Reduced MTHFR activity results in hyperhomocysteinemia, which is associated with cardiovascular disease. The AldoMet cycle's final product is the universal methyl donor for several biological methylation reactions. It is these methyl groups that form the basis for epigenetic modulation of DNA processes, which is beyond the scope of this review [59] .
MTHFR relies on dietary folate as well as genetic variants in determining its efficiency [60] . When inadequate amounts of 5-methyl THF are available for MTR, homocysteine increases and s-adenosyl methionine formation is reduced, resulting in DNA hypomethylation [61, 62] . Thus, folic acid plays an important role in maintaining genomic stability, as well as homocysteine levels [63] . Genetic variation within this enzyme has also been shown to affect its efficiency. For MTHFR, the 677C/T variant, resulting in an alanine-to-valine substitution, is the most prominent and produces a thermolabile variant with reduced activity [64] . The T allele is relatively common, with homozygosity occurring in up to 20 % of North American and European populations [58] . Individuals with a TT genotype have a 70 % reduction in MTHFR activity, compared with the CC genotype group, while heterozygotes have a 35 % reduction [65] . Of the AldoMet cycle enzymes, the MTHFR 677TT variant is the best characterized and is most consistently associated with hyperhomocysteinemia, cardiovascular disease, metabolic syndrome, and methylation status. This relationship is exaggerated by low dietary intake and reduced total body stores of folic acid [66] . Research currently points to MTHFR in the development of metabolic syndrome in mental health patients taking AAPs, as is summarized and discussed below [27, 30] . Pertinent to the metabolism of homocysteine is the enzyme catechol-O-methyltransferase (COMT). Despite the lack of clarity concerning COMT's role in the pathogenesis of schizophrenia, it has been shown that the 158Met variant produces a more thermolabile protein, resulting in reduced activity compared with the 158Val variant. Patients with the Val/Val genotype have 30-50 % greater activity than those with the Met/Met genotype [67] . Thus, in relation to homocysteine metabolism, individuals with the COMT 158Val allele would have higher COMT activity, leading to increased homocysteine concentrations, which may be exaggerated in individuals who also have MTHFR variants associated with hyperhomocysteinemia [68] . The risks seen with the AldoMet variants are often exaggerated in situations of low folate exposure [69] , and therefore dietary assessments, as well as genetic measurements, are dually important to the understanding of homocysteine, cardiovascular disease, and the risk of metabolic syndrome in patients receiving AAPs.
Role of Folic Acid in Atypical Antipsychotic
Metabolic Syndrome
Multiple studies have demonstrated relationships between MTHFR gene variants and schizophrenia pathogenesis, but more recently this work has begun to focus on the role of aberrant folate metabolism as it relates to the risk of metabolic syndrome in the schizophrenia population using AAPs. To identify the available literature associated with this topic, a PubMed search was conducted using combinations of the following terms: 'schizophrenia', 'folate', 'metabolic syndrome', 'antipsychotic', 'pharmacogenetic', 'epigenetic', 'MTHFR', 'COMT', and 'MTR'. A total of 22 studies were found; 15 were excluded because they were either not conducted in humans, were conducted without reference to antipsychotic use, were reviews, or did not relate to metabolic syndrome. Furthermore, the references of the included articles were searched for further literature sources. Table 2 is a summary of the studies on this topic that are discussed below. The first report of this relationship included 58 subjects with schizophrenia who were receiving AAPs. It was reported that patients with schizophrenia who carried a MTHFR 677T allele had a 3.6-fold risk of meeting metabolic syndrome criteria while taking an AAP (p = 0.02) [27] . Additionally, the data showed that after controlling for waist circumference, those with the MTHFR 677T allele were also at increased risk of developing higher levels of insulin resistance [27] . At that time, this report was the first to examine the relationship between MTHFR Fig. 1 The AldoMet cycle converts homocysteine into methionine and is facilitated by folate and methylenetetrahydrofolate reductase (MTHFR). Catechol-O-methyltransferase (COMT) converts methionine into S-adenyl methionine (SAM), also producing homocysteine. Genetic variants within these enzymes affect their efficiency within this cycle. THF tetrahydrofolate variants and the risk of metabolic syndrome within this population. This study was then followed up by Van Winkel et al. [70] . While this group also found a relationship between MTHFR and metabolic syndrome within schizophrenia, the authors reported that the presence of the MTHFR 1298A[C allele instead of the 677C[T allele was related to a significant increase in the risk of metabolic syndrome (p = 0.02). Overall, these authors found that patients with the 1298C/C genotype had a 2.4-fold increase in the risk of metabolic syndrome (p = 0.009), which was similar to our previously reported odds ratio of 2.54 for the 677T variant [27, 70] . Van Winkel et al. also conducted a prospective, naturalistic, 3-month follow-up study to evaluate the association between MTHFR 677C[T and 1298A[C variants and metabolic parameters after initiation of an AAP. In this study, they found genotype 9 time associations between the 1298A[C variant and measures of glucose, weight, and waist circumference. Although this study did not measure the occurrence of metabolic syndrome over time, it supports their earlier findings where schizophrenia patients with the 1298C allele had genetic loading for metabolic side effects from AAPs [71] . More recently, our group has gone on to confirm our initial findings in a separate group of 237 subjects with bipolar disorder or schizophrenia who were screened for metabolic syndrome and genotyped for both MTHFR and COMT variants. In addition, the subjects underwent a fairly comprehensive assessment for dietary and lifestyle factors (i.e. physical exercise, medication use, 24-h food recount, and smoking assessment), as well as folate exposure. Overall, 41 % of our subjects met metabolic syndrome criteria (n = 98). There were no significant differences in age, gender, AAP exposure, or body mass index between the different genotype groups. We found that the occurrence of metabolic syndrome was related to age, smoking, and the MTHFR 677T and COMT 158Val alleles (p \ 0.0001). Patients with these two risk alleles (the MTHFR 677T and COMT 158Val alleles) met metabolic syndrome criteria at a much earlier age than those without these alleles (46 vs. 52 years) [30] .
Additionally, studies have looked at the epigenetics of AAP-associated metabolic syndrome because of the link between folate pharmacogenetics and methylation, as described above. Epigenetics is a rapidly growing field in psychiatry because of the known influence of environment on mental illness, yet it requires cautious interpretation because of the complexities of epigenetic mechanisms and as study designs within schizophrenia continue to be defined [72] . One such study investigated the role of soluble COMT (COMT-s) methylation promoter status and metabolic syndrome in peripheral blood samples from schizophrenia patients largely on AAPs [73] . This study found that the COMT genotype was an indicator of the COMT methylation status of the two CpG sites that were investigated (p = 0.0044 for site 1; p = 0.027 for site 2). Furthermore, patients who were homozygous for the Met/ Met COMT genotype showed a positive correlation between CpG site methylation and metabolic syndrome (site 1: p = 0.001; site 2: p = 0.001). In addition to this investigation, a different study using peripheral blood samples found that females carrying the MTHFR 677TT genotype had the lowest measure of global methylation, measured using long interspersed nucleotide element-1 (LINE-1), which may help to explain the gender metabolic syndrome differences seen in schizophrenia [74] . Finally, investigators have reported that global DNA methylation (using a luminometric assay [LUMA]) differed on the basis of schizophrenia onset status as well as treatment type, with AAPs users having lower levels of global methylation [75] . Although this study did not look at metabolic indices, it did begin to show that methylation status can be affected not only by antipsychotic treatment but also by antipsychotic class.
Therefore, these studies provide evidence of a link between different enzymes related to folic acid metabolism and an increased risk of metabolic syndrome for patients with schizophrenia when taking an AAP. The results could possibly provide evidence for pharmacogenetic testing of patients before they start using antipsychotic medication, in an effort to reduce this risk or in addition to direct dietary and lifestyle interventions for those at greatest risk. Given that pharmacogenetic assays for MTHFR and its variants are commercially available and are often done within other medical specialties, the era of personalized medicine for schizophrenia may not be so far off.
Summary and Conclusions
It is now well known that use of AAPs is perhaps the most effective treatment we currently have for schizophrenia and other serious mental illnesses. Unfortunately, because of their associated risk of metabolic syndrome, use of these medications may be placing those individuals at greater risk of several comorbidities, resulting in an accumulation of life years lost because of cardiovascular disease. There currently is a lack of consensus regarding the specific criteria that should be used when diagnosing metabolic syndrome within the seriously mentally ill population, although some agreement does exist regarding which criteria are important and potentially place individuals at greater risk of development of cardiovascular disease. While monitoring guidelines for use of AAPs and the risk of metabolic syndrome have been developed and widely circulated, the reality is that, for many reasons, they are often not followed. Although many biomarkers have been proposed for possible prevention of metabolic syndrome seen with AAP use, this research has not successfully translated into clinical practice. The role of folic acid in the development of these metabolic complications is currently being investigated, and current data suggest that for patients with the MTHFR 677T and COMT 158Val alleles, the risk of metabolic syndrome may be elevated or may occur at a younger age. Furthermore, evidence is beginning to show that schizophrenia subjects reside in a global hypomethylation-and possibly less stable-genetic state. While the natural next step in this current research is folate supplementation, ongoing work in this area is not yet available. Studies of folate supplementation in schizophrenia patients using AAPs and carrying these increased risk pharmacogenomics and epigenomic targets are needed in order to begin to translate this research into practice. Thus, at this time, educating patients and their caregivers about the importance of a balanced healthy diet with exercise, as well as proper pharmacotherapeutic management of metabolic abnormalities, is crucial to combat the staggering cardiovascular mortality seen within this group. For patients whose diets do not include the minimum recommended daily allowance of folate, use of a supplement may be appropriate until conclusive data can be presented regarding the role of folic acid in the diagnosis and detection of metabolic syndrome within schizophrenia.
